In breast cancer pathology, IHC staining plays a pivotal role in treatment decisions and outcome prediction, particularly in determining molecular subtypes based on biomarkers such as ER, HER2, and PR (Cifci, Foersch & Kather, 2022). Here, ESR1 is linked to breast carcinoma.